Literature DB >> 8768833

Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo.

M Boscaro1, C Betterle, M Volpato, F Fallo, J Furmaniak, B Rees Smith, N Sonino.   

Abstract

Adrenal autoantibodies (ACA) are markers of adrenal cortex involvement in idiopathic Addison's disease. Recently the 21-hydroxylase (21-OH) enzyme has been discovered to be the major autoantigen of the ACA. A potential role of these antibodies in determining adrenal failure by inhibition of the 21-OH has been recently postulated. To test this hypothesis, cortisol and aldosterone (final products of adrenal steroid synthesis) and 17-hydroxyprogesterone (17-OH-progesterone) (as a marker of 21-OH impairment) have been investigated in baseline conditions and after ACTH (1-24) stimulation test in a group of 42 patients positive for both ACA and 21-OH autoantibodies. Patients were divided into five groups according to the stages (0-4) of adrenal failure. With progression toward overt Addison's disease, baseline 17-OH-progesterone, cortisol, and aldosterone remained almost unchanged but with impairment of their responses to ACTH (1-24) stimulation. The 17-OH-progesterone/cortisol ration remained normal both in basal conditions and after stimulation at stages 0-3. At stage 4 (overt Addison's disease), this ratio increased in baseline condition with no changes after ACTH (1-24), probably because of persistent 17-OH-progesterone gonadal production. In conclusion, there was a progressive and concomitant impairment of the synthesis of all steroids tested over various phases of adrenal failure. The pattern of response of the 17-OH-progesterone/cortisol ratio to ACTH stimulation in patients with 21-OH autoantibodies was not consistent with the autoantibodies inhibiting the 21-OH activity. This suggests that the inhibiting effect of 21-OH autoantibodies on 21-OH activity is not usually evident in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8768833     DOI: 10.1210/jcem.81.8.8768833

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity.

Authors:  P Peterson; J Pitkänen; N Sillanpää; K Krohn
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

2.  Assessment of adrenocortical function and autoantibodies in a baby born to a mother with autoimmune polyglandular syndrome Type 2.

Authors:  C Betterle; C Dal Pra; B Pedini; R Zanchetta; M P Albergoni; S Chen; J Furmaniak; B Rees Smith
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

3.  Inhibition of aromatic L-amino acid decarboxylase activity by human autoantibodies.

Authors:  E S Husebye; A S Boe; F Rorsman; O Kämpe; A Aakvaag; T Rygh; T Flatmark; J Haavik
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

Review 4.  The potential role for infections in the pathogenesis of autoimmune Addison's disease.

Authors:  A Hellesen; E Bratland
Journal:  Clin Exp Immunol       Date:  2018-09-30       Impact factor: 4.330

Review 5.  Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults.

Authors:  C Betterle; F Presotto; J Furmaniak
Journal:  J Endocrinol Invest       Date:  2019-07-18       Impact factor: 5.467

Review 6.  Autoimmune Addison disease: pathophysiology and genetic complexity.

Authors:  Anna L Mitchell; Simon H S Pearce
Journal:  Nat Rev Endocrinol       Date:  2012-01-31       Impact factor: 43.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.